GSK : FY guidance confirmed despite disappointments on Shingrix and Arexvy
>Q3 buoyed by speciality medicines - GSK has reported Q3 sales in line (+0.2% vs css) and above expectations on its core EPS (+14% vs css). Sales were up by 2% cc (-2% GBP) driven by a good performance from the specialty medicines division (19% cc, -0.5% vs cs) with an oncology franchise up by 94% cc (+2.8% vs css) and to a lesser extent from the general medicines division (+4% cc, +7% vs css) driven by Trelegy (16% cc). In contrast, the vaccine franchise disappointed...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.